Importantly, NKp30/ICOSL vIgD-Fc fusion proteins demonstrated anti-tumor efficacy in a B7 H6+ mouse tumor model, especially when administered in combination with a PD-1 inhibitor (Figure 1). Here, ICOSLG is linked to neoplasm.